Monday, October 21, 2019 7:20:51 PM
======================================
Done
- Efficacy (and FDA likes it even at higher dosage w/o new trial)
- CMO (IMHO also about to be done, stability data done EOY latest)
- Rolling review, FDA check when delivered
and allows correction (hence stability data completion)
TODO
- Safety (coming up soon Nov'19)
- Stability data until EOY '19
- Certain payments (CMO, ..)
- BLA completion paperwork
Lots of the delays occurred due to the open process (rolling review) with FDA, i.e. safety and stability.
This is usually where other stocks dip hard.
(CLSD got their CRL finally, besides stability one addition data request)
If issues can be cured quickly, market may forgive (CLSD, CYDY, ..)
Commercialization Outlook
=========================
Having one licensing partner signed an NBA. Ratification of final contract expected next week until end of month.
This NBA says partner takes costs for commercialization and gives a good chunk of royalties (50% on net sales).
No further financing needed for commercialization.
https://finesand.wordpress.com/2019/10/20/cytodyn-cydy-worst-case-valuation/
+++
Other parties are interested and received access to the data room.
Financing
==========
Independent of licensing partnership, CYDY needs $10M - $15M to complete the BLA until EOY 2019.
Even in the worst case $15M/$0.20 = 75M shares this won't dent the economics, calculated with 1B shares partnership model or 2B shares going alone.
Risks
======
(as I perceive them, none of them is very likely)
- No $15M financing available all of a sudden (after having raised over $200M??)
- FDA doesn't approve - doesn't likes the data (all of a sudden).
- Interested licensing partner runs away (why?)
- ????
Bottom Line
===========
This is a late stage company by now.
All elements of bringing a compound to market has been already addressed.
The only perceived weakness is
- weak balance sheet
- company and drug not well presented in the market yet
- management style, especially NP's way of talking
- poor funding instruments until licensing partnership
- tired investors listening to NP and waiting and waiting and waiting (o8>
Strength
- Strong acting drug w/o serious side effects
- Proven on HIV-1 Combo
- Lately proven w/ 700mg on HIV-1 Mono, but needs refined pivotal trial
- Drug also works in many other indications, including metastatic cancer
Big potential for a suitor.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/13/2024 04:15:06 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/07/2024 12:44:56 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/07/2024 12:42:22 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/15/2024 09:21:30 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/22/2024 01:00:58 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:17:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:16:28 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/09/2024 09:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 12:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM